Cargando…

Regional infusion of a class C TLR9 agonist enhances liver tumor microenvironment reprogramming and MDSC reduction to improve responsiveness to systemic checkpoint inhibition

Myeloid-derived suppressor cells (MDSCs) expand in response to malignancy and suppress responsiveness to immunotherapy, including checkpoint inhibitors (CPIs). Within the liver, MDSCs have unique immunosuppressive features. While TLR9 agonists have shown promising activities in enhancing CPI respons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghosh, Chandra C., Heatherton, Kara R., Connell, Kyle P. O’, Alexander, Ian S., Greer, Deborah A., LaPorte, Jason, Guha, Prajna, Cox, Bryan F., Katz, Steven C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750861/ https://www.ncbi.nlm.nih.gov/pubmed/35697801 http://dx.doi.org/10.1038/s41417-022-00484-z

Ejemplares similares

Assessing the Future of Solid Tumor Immunotherapy
por: Guha, Prajna, et al.
Publicado: (2022)

Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor Activity
por: Chai, Louis F., et al.
Publicado: (2021)

Motolimod, a selective TLR8 agonist induces apoptosis in monocytic myeloid-derived suppressor cells (M-MDSC)
por: Rutnam, Zina J, et al.
Publicado: (2015)

Critical immunosuppressive effect of MDSC-derived exosomes in the tumor microenvironment
por: Rashid, Mohammad H., et al.
Publicado: (2021)

Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints
por: Xu, Yaolin, et al.
Publicado: (2021)

Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx
por: Gandhi, Shipra, et al.
Publicado: (2023)

Increased MDSC Accumulation and Th2 Biased Response to Influenza A Virus Infection in the Absence of TLR7 in Mice
por: Jeisy-Scott, Victoria, et al.
Publicado: (2011)

Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors
por: Kapp, Kerstin, et al.
Publicado: (2019)

Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects
por: Li, Tianhang, et al.
Publicado: (2021)

Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients
por: Petrova, Vera, et al.
Publicado: (2023)

A TLR4 agonist improves immune checkpoint blockade treatment by increasing the ratio of effector to regulatory cells within the tumor microenvironment
por: Farias, A., et al.
Publicado: (2021)

Suppressing MDSC Recruitment to the Tumor Microenvironment by Antagonizing CXCR2 to Enhance the Efficacy of Immunotherapy
por: Bullock, Kennady, et al.
Publicado: (2021)

Suppressing MDSC Infiltration in Tumor Microenvironment Serves as an Option for Treating Ovarian Cancer Metastasis
por: Li, Yichen, et al.
Publicado: (2022)

Liposomal TLR9 Agonist Combined with TLR2 Agonist-Fused Antigen Can Modulate Tumor Microenvironment through Dendritic Cells
por: Shen, Kuan-Yin, et al.
Publicado: (2020)

Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery
por: Katz, Steven, et al.
Publicado: (2016)

TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy
por: Huang, Lan, et al.
Publicado: (2018)

Identification of an Immature Subset of PMN-MDSC Correlated to Response to Checkpoint Inhibitor Therapy in Patients with Metastatic Melanoma
por: Gondois-Rey, Françoise, et al.
Publicado: (2021)

MIF: metastasis/MDSC-inducing factor?
por: Simpson, Kendra D., et al.
Publicado: (2013)

Partners in crime: The feedback loop between metabolic reprogramming and immune checkpoints in the tumor microenvironment
por: Benito-Lopez, Jesus J., et al.
Publicado: (2023)

Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade
por: Conche, Claire, et al.
Publicado: (2023)

Circulating Myeloid Derived Suppressor Cells (MDSC) That Accumulate in Premalignancy Share Phenotypic and Functional Characteristics With MDSC in Cancer
por: Ma, Peiwen, et al.
Publicado: (2019)

TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy
por: Gonzalez, Caleb, et al.
Publicado: (2023)

G-MDSC-derived exosomes mediate the differentiation of M-MDSC into M2 macrophages promoting colitis-to-cancer transition
por: Wang, Yungang, et al.
Publicado: (2023)

PD-1/PD-L1, MDSC Pathways, and Checkpoint Inhibitor Therapy in Ph(-) Myeloproliferative Neoplasm: A Review
por: Wang, Jen-Chin, et al.
Publicado: (2022)

Catechins and antitumor immunity: Not MDSC’s cup of tea
por: Santilli, Giorgia, et al.
Publicado: (2013)

MDSC in Mice and Men: Mechanisms of Immunosuppression in Cancer
por: Vanhaver, Christophe, et al.
Publicado: (2021)

TLR9 Agonist Protects Mice from Radiation-Induced Gastrointestinal Syndrome
por: Saha, Subhrajit, et al.
Publicado: (2012)

Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model
por: Metzger, Philipp, et al.
Publicado: (2020)

Monocytic MDSC mobilization promotes tumor recurrence after liver transplantation via CXCL10/TLR4/MMP14 signaling
por: Liu, Hui, et al.
Publicado: (2021)

Ablative Radiotherapy Reprograms the Tumor Microenvironment of a Pancreatic Tumor in Favoring the Immune Checkpoint Blockade Therapy
por: Lee, Yu-Hung, et al.
Publicado: (2021)

Immune checkpoint blockade reprograms systemic immune landscape and tumor microenvironment in obesity-associated breast cancer
por: Pingili, Ajeeth K., et al.
Publicado: (2021)

An In Situ Autologous Tumor Vaccination with Combined Radiation Therapy and TLR9 Agonist Therapy
por: Zhang, Huagang, et al.
Publicado: (2012)

Neutrophils and Granulocytic MDSC: The Janus God of Cancer Immunotherapy
por: Zilio, Serena, et al.
Publicado: (2016)

Differentiation and Immunological Function of MDSC-Derived Dendritic Cells
por: Ding, Zequn, et al.
Publicado: (2022)

Editorial: The role of epigenetic modification in MDSC differentiation and function
por: Tian, Xinyu, et al.
Publicado: (2023)

Reprogramming the tumor microenvironment with biotechnology
por: Kim, Minjeong, et al.
Publicado: (2023)

Glycogen Metabolism Supports Early Glycolytic Reprogramming and Activation in Dendritic Cells in Response to Both TLR and Syk-Dependent CLR Agonists
por: Curtis, Kylie D., et al.
Publicado: (2020)

Metabolic reprogramming of the ovarian cancer microenvironment in the development of antiangiogenic resistance: Metabolic reprogramming of the OC microenvironment
por: Yue, Huiran, et al.
Publicado: (2023)

Targeting focal adhesion kinase reprograms the pancreatic tumor microenvironment and renders pancreas cancer responsive to checkpoint immunotherapy
por: Jiang, Hong, et al.
Publicado: (2015)

Deoxyguanosine is a TLR7 agonist
por: Davenne, Tamara, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_eus8qujo9tua1ogqp9k2rjqnj0